STRM.BIO Raises $8 Million in Series Seed 2 Financing to Advance Non-Viral Gene Delivery Platform for In Vivo Cell Engineering and Gene Therapy

STRM.BIO, a biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today ...
Seeking Alpha

Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program

BOSTON, Oct. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks today announced a collaboration with STRM.BIO and the University of British Columbia (UBC) as part of the Advanced Research Projects Agency for ...
Seeking Alpha

STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy

CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- STRM.BIO, a start-up biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced that it has been ...
FOX31 Denver

STRM.BIO Appoints Independent Director Dawn Bell, PharmD, to its Board

BOSTON, May 17, 2023 /PRNewswire/ -- STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new therapeutics ...
FOX59 News

STRM.BIO Appoints Independent Director Minnie Mildwoff, to its Board of Directors

BOSTON, July 24, 2023 /PRNewswire/ -- STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new ...
WREG

STRM.BIO Presents Preclinical Data on a Novel Bone Marrow/HSPC-Targeted, Megakaryocyte-Derived Extracellular Vesicle Delivery Platform for In Vivo Gene Therapy at the Cell ...

BOSTON, Oct. 11, 2023 /PRNewswire/ -- STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new ...
KTLA

STRM.BIO Presents First Preclinical Data on a Novel Bone Marrow/Hematopoietic Stem Cell-Targeted Extracellular Vesicle Delivery Platform for In Vivo Gene Therapy at ASH 2023

BOSTON, Dec. 11, 2023 /PRNewswire/ -- STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new ...
Yahoo Finance

STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy

STRM.BIO's MV platform represents a novel, cell-derived delivery modality with the potential to overcome many of the key barriers limiting current viral and synthetic in vivo delivery systems. "This ...